Large-scale cancer genomics and genome-wide studies of the chromatin and DNA methylation landscape are reshaping our understanding of tumor heterogeneity, evolution, and genome stability. It is clear that epigenetic regulators are critical mediators of cancer progression and drug resistance, and new classes of targeted therapeutics against epigenetic regulators are already in clinical trials.

Our goal in organizing this meeting is to gather together experts on cancer, genomics, chromatin, systems biology, and chemical biology to discuss the rapidly advancing field of cancer epigenomics and its imminent impact on new cancer therapies. We aim to provide a forum for discussion and potential future collaboration amongst clinicians, drug development companies, and those at the forefront of basic biological discovery. The ultimate goal is to advance this exciting aspect of cancer biology and inform the epigenetic cancer therapies of tomorrow.

We hope you can join us in Spain in October.

The organizing committee:
Ann Cheung, Scientific Editor, Cancer Cell
Manel Esteller, IDIBELL, Spain
Liz Gaskell, Scientific Editor, Molecular Cell
Richard Young, Whitehead Institute and MIT, USA

Preliminary Program

Sunday, October 6, 2013
	Registration
	Welcome and introduction
	Session 1: Cancer genomics, epigenomics, and epigenetic drivers
	KEYNOTE: Stephen Baylin, Johns Hopkins, USA
	Lynda Chin, MD Anderson, USA
	Susan Clark, Garvan Institute of Medical Research, Australia
	Bing Ren, University of California San Diego, USA
	Selected short talk
	Poster teasers
	Drinks reception
Monday, October 7, 2013
	Session 2: Epigenetic influences on genome stability
	Emily Bernstein, Mount Sinai, USA
	Jan Korbel, EMBL, Germany
	Ben Lehner, Center for Genomic Regulation, Spain
	Selected short talk
	Lunch
	Poster session I
	Session 3: Molecular underpinnings of therapeutic targets
	KEYNOTE: Jay Bradner, Dana-Farber Cancer Institute and Harvard Medical School, USA
	Dash Dhanak, GlaxoSmithKline, USA
	Tony Kouzarides, The Gurdon Institute, UK
	Christopher Vakoc, Cold Spring Harbor Laboratory, USA
	Richard Young, Whitehead Institute and MIT, USA
	Selected short talk
	Meet the speakers dinner
Tuesday, October 8, 2013
	Session 4: Aberrant DNA methylation in cancer
	Stephan Beck, University College London, UK
	Manel Esteller, IDIBELL, Spain
	Kristian Helin, University of Copenhagen, Denmark
	Craig Thompson, Memorial Sloan-Kettering Cancer Center, USA
	Selected short talk
	Lunch
	Poster Session II
	Session 5: Tumor heterogeneity
	Thomas Graf, Center for Genomic Regulation, Spain
	Piyush Gupta, Whitehead Institute and MIT, USA
	Nicholas Navin, MD Anderson, USA
	Fiona Watt, King’s College London, UK
	Selected short talk
	Closing remarks

^ Go to Top